RLAY (RLAY) Stock Analysis
Verdict: HOLD
Clinical milestone momentum in PI3Ka/FGFR2 is offset by $235M annual cash burn and relentless insider selling near 52-week highs.
Investment score: 43/100
Is RLAY Stock Worth Reviewing? AI Model Thesis
The AI model maintains a HOLD rating on Relay Therapeutics (RLAY) with an Investment Score of 43/100. Positive clinical pipeline advancement is balanced by persistent operating losses (-$302.74M in 2025) and heavy insider selling.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| TNGX | -28.71 | 3.57 | 73.82 | -29.92 | — | -2.30 |
| PBLS | -0.89 | 0.91 | 25951.37 | -29.16 | — | -660.67 |
| VKTX | -7.31 | 9.67 | 0.00 | -7.21 | — | 0.00 |
| CELC | -18.62 | -342.51 | 0.00 | -24.11 | — | 0.00 |
| VCYT | 31.78 | 2.63 | 6.50 | 26.14 | — | 0.20 |
Should You Buy or Sell RLAY Stock? Model Reasoning
The model views Relay Therapeutics as a HOLD at $17.79. While clinical platform progress and $578.28M in current assets support a ~2.4-year cash runway, the business remains pre-commercial with an annual FCF burn of -$235.87M. Overwhelming insider liquidation (31 sells vs 0 buys, including SVF Pauling dumping 6M shares at $19.40) and 3 EPS misses in the last 4 quarters suggest distribution at current elevated valuation levels (P/B 4.05x vs peer TNGX 3.57x).
RLAY Fair Value & Price Target — AI Valuation
- Model Assumptions: ["RLY-2608 maintains a ~30% risk-adjusted probability of achieving regulatory approval in PI3Kα-mutant breast cancer.","Annual operating cash burn remains bounded between -$235M and -$250M, maintaining liquidity through late 2027 without near-term equity dilution.","Consensus top-line expectations of $20M in 2027 and $160M in 2029 materialize as out-licensing royalties or milestone triggers."]
RLAY Risk & Opportunity Analysis
Key Investment Risks
- Relentless cash burn rate ($235.87M annually) and commercial gap — Relay burned -$235.87M in free cash flow in 2025 while generating just $15.36M in annual revenue. Failure to secure non-dilutive licensing or reach commercialization by 2027 would force equity dilution at unfavorable market valuations.
- Massive net insider liquidation and SoftBank exit — Insiders have completed 31 sell transactions with 0 buys, including major holder SVF Pauling liquidating 6.0M shares at $19.40 and CEO Sanjiv Patel selling 48,199 shares at $18.94 in September 2026, signaling limited management confidence above $18.50.
- Binary Phase 2/3 clinical trial execution risk — If lead candidates RLY-4008 or RLY-2608 fail to achieve key primary endpoints in ongoing clinical trials, equity value could drop significantly given the pre-revenue TTM operating margin of -2999.4%.
- Elevated price-to-book valuation relative to peer group — At P/B of 4.05x and P/S of 376.27x, RLAY trades at a valuation premium to clinical-stage precision peers like TNGX (P/B 3.57x, P/S 73.82x), leaving minimal safety margin if revenue targets lag 2029 consensus estimates ($160M).
Growth Opportunities & Upside Drivers
- RLY-2608 mutant-selective PI3Ka pipeline validation — If RLY-2608 demonstrates superior isoform selectivity over conventional non-selective PI3K inhibitors, Relay can capture market share in HR+/HER2- breast cancer targets by 2028-2029, supporting consensus revenue forecasts of $160M by 2029.
- Robust working capital runway through 2028 — With $578.28M in current assets against $25.58M in current liabilities as of late 2025, Relay possesses approximately 2.4 years of liquidity against its annual FCF burn rate of -$235.87M, minimizing immediate dilution risk until late 2027.
- Strong Wall Street analyst endorsement — 19 of 20 covering analysts rate RLAY as Buy or Strong Buy, with a consensus target of $26.25 (+47.5% upside from $17.79), offering potential institutional buying support on clinical trial pullbacks.
- Strategic partnerships expanding clinical validation — Milestone events such as X-Chem's Phase 3 collaboration milestone announced September 22, 2026, and ongoing Genentech agreements reduce total R&D funding pressure while providing non-dilutive capital injections.
RLAY Action Plan — Entry, Exit and Stop Loss from the Model View
moderate
aggressive
conservative
Frequently Asked Questions About RLAY (RLAY)
Is RLAY stock a good investment?
The cached TradeMates AI model rates RLAY as HOLD with an investment score of 43/100. The AI model maintains a HOLD rating on Relay Therapeutics (RLAY) with an Investment Score of 43/100. Positive clinical pipeline advancement is balanced by persistent operating losses (-$302.74M in 2025) and heavy insider selling. This is algorithmic model output, not personal investment advice.
Does RLAY pay a dividend?
The cached stock data on this page does not show a positive dividend yield for RLAY. Dividend status can change, so verify the latest company filings before relying on income assumptions.
What does RLAY stock do?
Clinical-stage precision biopharmaceutical company leveraging the computational 'Dynamix' platform to discover small molecule drugs targeting mutant oncology pathways (PI3Kα, FGFR2, SHP2); revenues stem entirely from non-recurring licensing and milestone payments from partners such as Genentech.
What is RLAY stock's price target?
This cached page does not contain a precise model fair value for RLAY.
Is RLAY stock a buy?
The TradeMates model verdict for RLAY is HOLD with an investment score of 43/100. Treat this as a model signal to review, not a personal buy recommendation.
Is RLAY a good dividend stock?
RLAY is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.